Answers are grounded in this paper and cite their sources.
Background Still’s disease can remain severe despite sequential targeted therapies, and prolonged glucocorticoid exposure remains a major clinical problem. We aimed to describe reported clinical outcomes, safety events, and changes in glucocorticoid use associated with intentional concurrent treatment with at least two targeted agents in Still’s disease. Methods We report two novel pediatric cases and a systematic review of reports of concurrent treatment with more than one biologic and/or targeted synthetic disease-modifying antirheumatic drug in Still’s disease. PubMed, Web of Science, and the Cochrane Library were searched from inception to August 16, 2026. Eligible reports included patients with pediatric-onset Still’s disease (POSD) or adult-onset Still’s disease (AOSD) receiving concurrent targeted therapy (CTT) and reporting at least one clinical, laboratory, steroid-related, or safety outcome. Findings We identified 636 records and screened 469 after deduplication; 11 reports met the inclusion criteria. Together with two new pediatric cases, 25 patients were included, of whom 16 had POSD and nine had AOSD. Of these, 18 were female patients and seven were male patients. The median number of prior treatment lines was four. Source authors reported clinical improvement in 17 of 25 patients and remission in nine of 18; these categories overlapped, and remission could not be verified against standardized criteria. Macrophage activation syndrome (MAS) had been reported before CTT in nine of 23 patients. After treatment initiation, further MAS episodes were documented in one patient, but heterogeneous follow-up and incomplete recurrence reporting precluded calculation or comparison of event rates. Glucocorticoid tapering or dose reduction was reported in 22 of 25 patients, and absence of regular systemic glucocorticoids at last follow-up was reported in nine of 16 patients with POSD and one of nine with AOSD. Two serious adverse events were reported, both in adult-onset patients; however, limitations of the case-based evidence preclude reliable assessment of adverse-event incidence or comparative safety. Interpretation CTT was used mainly as an experimental rescue strategy in highly selected patients with difficult-to-treat Still’s disease. Reported clinical improvement and glucocorticoid reduction were temporally associated with treatment, but the limited, uncontrolled, case-based evidence does not establish efficacy, prevention of MAS, or comparative safety. Apparent differences between POSD and AOSD are exploratory and should not be interpreted as evidence of biological differences. CTT use should be restricted to expert centers, and prospective studies with standardized outcomes and safety ascertainment are required.
No takes yet. Share an insight, caveat, or question.
Opitz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: